

**Can't Stop, Won't Stop the Search for Relief: Scratching the Surface of Itch
& Inflammation in Moderate-to-Severe Atopic Dermatitis
Tweeterial #2 Reference List**

Tweet #2:

Wei W, Ghorayeb E, Andria M, et al. *Ann Allergy Asthma Immunol*. 2019;123(4):381-388.e2.

Tweet #4:

Renert-Yuval Y, Guttman-Yassky E. New treatments for atopic dermatitis targeting beyond IL-4/IL-13 cytokines. *Ann Allergy Asthma Immunol*. 2020;124(1):28-35.

Tweet #5:

Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. *Lancet*. 2017 Jun;389(10086):2287-2303.
Simpson EL, Bieber T, Guttman-Yassky E, et al. Two Phase 3 trials of dupilumab versus placebo in atopic dermatitis. *N Engl J Med*. 2016;375:2335-2348.

Tweet #6:

Beck LA, Silverberg JI, Simpson EL, et al. Dupilumab significantly improves sleep outcomes in adult patients with atopic dermatitis: results from five randomized clinical trials. *J Eur Acad Dermatol Venereol*. 2020 Aug 12. Online ahead of print. doi:10.1111/jdv.16865.

Silverberg JI, Yosipovitch G, Simpson EL, et al. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS. *J Am Acad Dermatol*. 2020;82(6):1328-1336.

Tweet #7:

Alexis AF, Rendon M, Silverberg JI, et al. Efficacy of dupilumab in different racial subgroups of adults with moderate-to-severe atopic dermatitis in three randomized, placebo-controlled phase 3 trials. *J Drug Dermatol*. 2019 Aug;18(8):804-813.

Tweet #8:

Ou Z, Chen C, Chen A, Yang Y, Zhou W. Adverse events of dupilumab in adults with moderate-to-severe dermatitis: A meta-analysis. *Int Immunopharmacol*. 2018 Jan;54:303-310.

Tweet #9:

Kabashima K, Matsumura T, Komazaki H, Kawashima M for the Nemolizumab -JP01 Study Group. Trial of nemolizumab and topical agents for atopic dermatitis with pruritus. *N Engl J Med*. 2020;383:141-150; 2020. Nemolizumab For Atopic Dermatitis [video]. <https://www.nejm.org/doi/10.1056/NEJMdo005772/full/>

Tweet #10:

Tralokinumab achieves primary and secondary endpoints in three pivotal phase 3 trials in adult patients with moderate-to-severe atopic dermatitis. *Business Wire*. June 12, 2020. Accessed September 13, 2020. <https://www.businesswire.com/news/home/20200612005247/en/Tralokinumab-Achieves-Primary-Secondary-Endpoints-Pivotal-Phase/>